Neuroprotexeon
NeuroproteXeon (NP) is a Buffalo, New York based company developing the use of Xenon gas as a neuroprotective agent in patients suffering from neurological injury. Xenon is delivered through an Inhalation device to patients following critical neurological injury, reducing cell damage.
The use of xenon as a neuroprotective agent is aimed to improve mortality rates and neurological function in patients experiencing acute injury to the brain.[1]
Developed by company founders Mervyn Maze, MB, ChB and Nicholas Franks FRS, it is currently preparing for a Phase III clinical trial in Out-of-Hospital Cardiac Arrest (OHCA) patients.[2]
Xenon as anesthetic
Xenon has been used for over 60 years as an anesthetic. It has proven to have cardioprotective and neuroprotective properties. The use of xenon gas in conjunction with hypothermia has demonstrated positive neuroprotective properties.[3]
Clinical trials
Positive preclinical work has led to Phase II trials designed to study the effects of xenon use on brain tissue.[4][5][6] Results of Phase II trials are forthcoming.
NeuroproteXeon is initially pursuing two indications: cardiac arrest and anesthetic-induced developmental neurotoxicity (AIDN). Current preparations are for a Phase III clinical trial in out-of-hospital cardiac arrest (OHCA) patients.
Founders
Mervin Maze, MD, Chief Medical Officer, co-inventor of the company’s xenon neuroprotective technology and of Precedex™ (dexmedetomidine), a sedative medication used by intensivists and anesthesiologists. Maze has served as Chair of Anesthesia and Critical Care at Imperial College, London and the University of California, San Francisco, where he is an Endowed Tenured Professor of Anesthesia.
Nicholas Franks, FRS, Chairman, NeuroproteXeon Founder. Franks is a biophysicist and Head of Biophysics at Imperial College, London. He is a filer of patents on xenon for neuroprotection.
References
- ↑ Esencan, E (2013). "XENON in medical area: emphasis on neuroprotection in hypoxia and anesthesia". Medical Gas Research. Feb 1;3: 3–4. doi:10.1186/2045-9912-3-4. Retrieved 26 February 2016.
- ↑ http://patents.com/us-7390508.html. Use of xenon with hypothermia for treating neonatal asphyxia. June 24, 2008. (Portuguese Patent No.: PT1670489 [E]; February 28, 2008.)
- ↑ Cullen, S (1951). "The anesthetic properties of xenon in animals and human beings, with additional observations on krypton". Science. 113: 580–2.
- ↑ Maze, Mervin (2015). "Preclinical neuroprotective actions of xenon and possible implications for human therapeutics: a narrative review". Canadian Journal of Anesthesiologists. 63 (February): 212–216.
- ↑ https://clinicaltrials.gov/ct2/show/NCT01120405. Missing or empty
|title=(help) - ↑ Sanders, R (2005). "Xenon: elemental anaesthesia in clinical practice". Oxford Journals. 71 ((1)): 115–135.
External links
This article "Neuroprotexeon" is from Wikipedia. The list of its authors can be seen in its historical. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
